Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jan 1;17(2):656-69.
doi: 10.2741/3950.

Uric acid, hyperuricemia and vascular diseases

Ming Jin  1 , Fan Yang, Irene Yang, Ying Yin, Jin Jun Luo, Hong Wang, Xiao-Feng Yang
Affiliations
Review

Uric acid, hyperuricemia and vascular diseases

Ming Jin et al. Front Biosci (Landmark Ed). .

Abstract

Uric acid is the product of purine metabolism. It is known that hyperuricemia, defined as high levels of blood uric acid, is the major etiological factor of gout. A number of epidemiological reports have increasingly linked hyperuricemia with cardiovascular and neurological diseases. Studies highlighting the pathogenic mechanisms of uric acid point to an inflammatory response as the primary mechanism for inducing gout and possibly contributing to uric acid's vascular effects. Monosodium urate (MSU) crystals induce an inflammatory reaction, which are recognized by toll-like receptors (TLRs). These TLRs then activate NALP3 inflammasome. MSU also triggers neutrophil activation and further produces immune mediators, which lead to a proinflammatory response. In addition, soluble uric acid can also mediate the generation of free radicals and function as a pro-oxidant. This review summarizes the epidemiological studies of hyperuricemia and cardiovascular disease, takes a brief look at hyperuricemia and its role in neurological diseases, and highlights the studies of the advanced pathological mechanisms of uric acid and inflammation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1. Biosynthesis of uric acid
Abbreviations: AMP: adenosine monophosphate; IMP: inosine monophosphate; XMP: xanthosine monophosphate; GMP: guanosine monophosphate; NT: nucleotidase; PNP: purine nucleoside phosphorylase; HGPRT: hypoxanthine-guanine phosphoribosyltransferase
Fig. 2
Fig. 2
Mechanisms and pathways in MSU-mediated inflammation
Fig. 3
Fig. 3
Hyperuricemia and diseases
See this image and copyright information in PMC

References

    1. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004;31:1582–7. - PubMed
    1. Becker M, Roessler BJ. Hyperuricemia and gout. In: C. B. Scriver AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. McGraw-Hill; 1995. pp. 1655–1677.
    1. Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol. 1988;41:237–42. - PubMed
    1. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. 2008;168:1104–10. - PubMed
    1. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54:2688–96. - PubMed

MeSH terms